Clinical trials: Biochemically Recurrent Prostate Cancer, active
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT06205316
- Testing
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Mayo Clinic
Prostate Cancer Recurrent
PSMA-RLT in Biochemically Recurrent PCa
Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA > nadir + 2ng/ml after radiotherapy (RT)…
- Trial name
- NCT06220188
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Prostate
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a…
- Trial name
- NCT03047135
- Testing
- Olaparib
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
A Single-center Prospective Interventional Study on FPG500 in Non-metastatic Prostate Cancer Patients
The search for clinically actionable alterations within the non-metastatic prostate cancer setting has been an overlooked issue so far.
- Trial name
- NCT06875297
- Testing
- FPG500
- Where
- Italy
- Volunteers
- 184 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer
Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer
The goal of this observational study is to use an artificial intelligence-based platform, integrating clinical, pathologic, imaging, genomic and transcriptomic profiles of prostate cancer in order to outperform currently…
- Trial name
- PRISM-AI (NCT06468332)
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer, High-risk Biochemical Recurrence
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
- Conditions
- Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT06555796
- Testing
- Xaluritamig
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Recurrent Prostate Cancer
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent.
- Trial name
- TerbinaPro (NCT07365423)
- Testing
- Terbinafine
- Where
- 11 sites in Switzerland
- Volunteers
- 42 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer, Biochemically Recurrent
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
Background: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans…
- Trial name
- NCT05588128
- Testing
- 18F-DCFpyL
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Patients, Non-metastatic Prostate Cancer
Radiation Therapy Approaches for People With Prostate Cancer
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
- Conditions
- Prostate Cancer Patients, Non-metastatic Prostate Cancer, High Risk Prostate Cancer
- Trial name
- NCT07751159
- Testing
- Standard of Care HDR Brachytherapy, SBRT
- Where
- 7 sites in United States
- Volunteers
- 126 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Prostate Cancer, Prostate Cancer
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Background: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year.
- Trial name
- NCT07686380
- Testing
- N-803, ETBX-71 Vaccine, 18F-DCFPyL
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
Various approaches are currently being developed for prostate cancer immunotherapy. However, a major challenge facing the development of cancer immunotherapy is the identification of tumors that would best respond to this type of…
- Trial name
- PICT-01 (NCT04009967)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07073794
- Testing
- Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Locally Recurrent Cancer
Study on Prostate Salvage Using High-dose-rate Brachytherapy
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and…
- Conditions
- Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation
- Trial name
- PROSCATE (NCT07860528)
- Where
- 10 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Biochemical Recurrent Prostate Cancer
Radium-223 in Biochemically Recurrent Prostate Cancer
Background: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer.
- Trial name
- NCT04206319
- Testing
- Radium-223, 18F Sodium Fluoride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
RElugolix VErsus LeUprolide Cardiac Trial
This clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer undergoing…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- REVELUTION (NCT05320406)
- Testing
- Radiation therapy, Leuprolide, Relugolix
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Emory University